AT7 Antibody

What is TAT-AT7 and how does it differ structurally from AT7 alone?

TAT-AT7 is a chimeric peptide created by attaching the cell-penetrating peptide TAT to the vascular-targeting peptide AT7. This fusion combines the BBB-penetrating capabilities of TAT with the vascular-targeting properties of AT7, creating a dual-function molecule. The structural integration of these two peptides allows TAT-AT7 to effectively cross the blood-brain barrier while maintaining specific binding to vascular targets .

The experimental evidence demonstrates that TAT-AT7 exhibits significantly enhanced activity compared to either AT7 or TAT alone, as well as to a physical mixture of both peptides (TAT+AT7). This indicates that the chimeric structure provides functional advantages beyond the simple combination of its components .

What are the primary molecular targets of TAT-AT7?

TAT-AT7 primarily targets two receptors that play critical roles in angiogenesis:

• Vascular endothelial growth factor receptor 2 (VEGFR-2)

• Neuropilin-1 (NRP-1)

Both receptors are highly expressed in endothelial cells and are central to vascular development. Surface plasmon resonance (SPR) assays have confirmed that TAT-AT7 competitively binds to these receptors, effectively preventing VEGF-A165 from binding and initiating angiogenic signaling cascades .

It's important to note that while NRP-1 lacks consensus signaling domains, it serves as a co-receptor for VEGF-A165 and enhances VEGF-A165-induced VEGFR-2 downstream signal transduction that promotes angiogenesis .

How does TAT-AT7's BBB-penetrating ability compare to other targeting peptides?

TAT-AT7 demonstrates superior BBB-penetrating capabilities compared to AT7 alone. In orthotopic U87-glioma-bearing nude mice models, fluorescently labeled TAT-AT7 (FITC-TAT-AT7) exhibited significantly higher accumulation in glioma tissue compared to FITC-AT7 and FITC-TAT .

Immunohistochemical analysis revealed that TAT-AT7 was able to effectively co-localize with glioma blood vessels (identified by CD31 staining), whereas AT7 alone showed very weak fluorescence in glioma tissue, primarily due to its poor ability to penetrate the BBB .

This enhanced BBB penetration is a critical advantage for therapeutic applications targeting brain tumors, as it allows for more efficient delivery of the active agent to the tumor site.

What in vitro assays are most informative for evaluating TAT-AT7's anti-angiogenic effects?

To comprehensively assess TAT-AT7's anti-angiogenic properties, researchers should employ the following battery of in vitro assays:

Experimental design should include proper controls: untreated cells, cells treated with AT7 alone, TAT alone, and a physical mixture of TAT+AT7 to demonstrate the specific effects of the chimeric peptide versus its components .

How should researchers design SPR experiments to evaluate the competitive binding of TAT-AT7 to VEGFR-2 and NRP-1?

Surface plasmon resonance (SPR) assays are critical for understanding the binding kinetics and competitive interactions between TAT-AT7 and VEGF-A165. A methodologically sound SPR experimental design should include:

• Immobilization of recombinant VEGFR-2 and NRP-1 separately on sensor chips

• Concentration gradient testing of TAT-AT7 (typically 10-fold dilutions from 1 μM to 0.1 nM)

• Competitive binding experiments with:

  • Pre-mixing TAT-AT7 with VEGF-A165 at various molar ratios

  • Sequential injections of TAT-AT7 followed by VEGF-A165 (and vice versa)

• Control experiments with AT7 alone, TAT alone, and TAT+AT7 mixture

• Data analysis to determine:

  • Association (k_on) and dissociation (k_off) rate constants

  • Equilibrium dissociation constant (K_D)

  • Competitive binding inhibition constants (K_i)

This experimental approach allows for quantitative assessment of the binding affinity and competitive inhibition properties of TAT-AT7 against VEGF-A165 .

What are the critical parameters for zebrafish embryo models when evaluating TAT-AT7's anti-angiogenic effects?

The zebrafish embryo model provides an excellent in vivo system for assessing anti-angiogenic effects. Key methodological considerations include:

• Embryo selection: Use 24 hours post-fertilization (hpf) embryos for consistency

• Treatment concentrations: Test TAT-AT7 in range of 5-100 μmol/L

• Exposure duration: 24-48 hours of treatment

• Visualization method: Use transgenic Tg(fli1:EGFP) zebrafish for direct fluorescent visualization of vasculature

• Quantification parameters:

  • Intersegmental vessel (ISV) count and morphology

  • Dorsal longitudinal anastomotic vessel (DLAV) formation

  • Subintestinal vein (SIV) basket development

• Control groups: Untreated embryos, embryos treated with AT7, TAT, or TAT+AT7 mixture

• Statistical analysis: Minimum 20 embryos per treatment group for statistical power

How does TAT-AT7 inhibit VEGF-A165 binding and subsequent signal transduction?

TAT-AT7 inhibits VEGF-A165 binding through a dual mechanism of action:

• Competitive Binding: TAT-AT7 directly competes with VEGF-A165 for binding sites on both VEGFR-2 and NRP-1. SPR assays have demonstrated that TAT-AT7 effectively prevents VEGF-A165 from binding to these receptors .

• Downstream Signaling Inhibition: The binding of TAT-AT7 inhibits the phosphorylation of VEGFR-2, which prevents the activation of several downstream signaling cascades. Specifically, TAT-AT7 inhibits the phosphorylation of:

  • PLC-γ (involved in calcium signaling and PKC activation)

  • ERK1/2 (regulates cell proliferation)

  • SRC (mediates cell migration)

  • AKT (controls cell survival)

  • FAK kinases (regulates cell adhesion and migration)

By blocking both receptor binding and downstream signaling activation, TAT-AT7 comprehensively inhibits the pro-angiogenic effects of VEGF-A165.

What is the relationship between TAT-AT7's structure and its ability to inhibit multiple endothelial cell functions?

The chimeric structure of TAT-AT7 enables its multifunctional inhibitory effects on endothelial cells through several structure-function relationships:

• The TAT component facilitates cellular uptake and BBB penetration, allowing the peptide to reach its target tissues and cells more effectively

• The AT7 component provides specific binding to VEGFR-2 and NRP-1

• The combined structure creates a molecular entity that:

  • Inhibits endothelial cell proliferation in a concentration-dependent manner (>50% inhibition at 320 μmol/L)

  • Significantly reduces cell migration in wound healing assays

  • Decreases invasive capacity in transwell invasion assays

  • Disrupts tube formation on Matrigel, reducing total branch length

  • Promotes endothelial cell apoptosis

The superior efficacy of TAT-AT7 compared to AT7 alone, TAT alone, or even their physical mixture (TAT+AT7) demonstrates that the chimeric structure provides synergistic advantages that enhance its anti-angiogenic properties .

What are the optimal parameters for evaluating TAT-AT7 efficacy in orthotopic glioma models?

For rigorous evaluation of TAT-AT7 in orthotopic glioma models, researchers should consider the following methodological framework:

Animal Model Selection and Setup:

• Use nude mice with orthotopic U87-mCherry-luc glioma cells for both imaging capabilities and immune tolerance

• Establish consistent tumor implantation techniques (stereotactic injection coordinates and cell number)

• Allow sufficient time for tumor establishment (typically 7-10 days) before treatment initiation

Treatment Protocol:

• Dose range determination based on preliminary PK/PD studies

• Administration route: intravenous tail injection for systemic delivery

• Treatment schedule: determine optimal frequency and duration

• Control groups: vehicle control, AT7 alone, TAT alone, TAT+AT7 mixture

Efficacy Assessment Parameters:

• Tumor growth monitoring:

  • Bioluminescence imaging for longitudinal monitoring

  • MRI for volumetric assessment

• Survival analysis

• Tissue analysis:

  • Vascular density (CD31 staining)

  • Tumor cell proliferation (Ki-67)

  • Apoptosis markers (TUNEL assay)

• Distribution analysis:

  • FITC-labeled peptide tracking

  • Co-localization with vascular markers

How does TAT-AT7 distribution in glioma tissue compare to its distribution in normal brain tissue?

TAT-AT7 demonstrates preferential accumulation in glioma tissue compared to normal brain tissue, which is critical for therapeutic applications. The distribution pattern shows:

• Significantly higher green fluorescence intensity (from FITC-TAT-AT7) in glioma tissue compared to normal brain parenchyma

• Distinct co-localization with glioma blood vessels (identified by CD31 immunohistochemical staining)

• Enhanced permeability across the blood-brain barrier specifically in the tumor region, where the BBB is often compromised

• Greater tissue penetration depth in glioma compared to surrounding normal tissue

This preferential distribution pattern suggests that TAT-AT7 could provide targeted therapy with reduced effects on normal brain tissue, potentially minimizing off-target toxicity in clinical applications.

What comparative advantages does TAT-AT7 offer over other anti-angiogenic approaches for glioma treatment?

TAT-AT7 offers several distinct advantages over other anti-angiogenic approaches for glioma treatment:

These advantages, particularly the enhanced BBB penetration and potential for use as a gene delivery vehicle, position TAT-AT7 as a promising approach for the challenging context of glioma treatment .

How should researchers analyze TAT-AT7 dose-response data to determine optimal concentrations for different experimental contexts?

Proper analysis of TAT-AT7 dose-response data requires a systematic approach to determine optimal concentrations for various experimental contexts:

• Establish a wide concentration range:

  • In vitro studies should test concentrations from 10-320 μmol/L

  • In vivo studies may require preliminary PK/PD analysis to determine relevant tissue concentrations

• Generate complete dose-response curves:

  • Plot inhibition percentage versus log concentration

  • Calculate IC50 values (concentration causing 50% inhibition) for each assay type

• Identify threshold concentrations:

  • For TAT-AT7, concentrations above 40 μmol/L show significantly higher inhibition rates compared to AT7, TAT, or TAT+AT7 groups

  • At 320 μmol/L, TAT-AT7 demonstrates >50% inhibition of endothelial cell proliferation

• Perform comparative analysis:

  • Statistical comparison between TAT-AT7 and control groups at each concentration

  • Evaluate slope differences in dose-response curves to assess potency

• Context-specific optimization:

  • For migration/invasion assays: determine minimum concentration with significant effect

  • For apoptosis studies: identify concentration threshold triggering programmed cell death

  • For in vivo studies: calculate dose equivalent based on in vitro optimal concentrations

What statistical approaches are most appropriate for analyzing complex TAT-AT7 experimental data?

Analyzing complex TAT-AT7 experimental data requires appropriate statistical methodologies depending on the experimental design:

Sample size determination should be based on power analysis, with α=0.05 and power (1-β)=0.8 as standard thresholds for detecting biologically meaningful differences .

How can TAT-AT7 be utilized as a delivery vehicle for anti-glioma therapeutics?

TAT-AT7 can serve as an effective delivery vehicle for anti-glioma therapeutics through several strategic approaches:

• Gene Delivery Applications:

  • TAT-AT7 has been successfully used to deliver the secretory endostatin gene to glioma cells via TAT-AT7-modified polyethyleneimine (PEI) nanocomplexes

  • The dual targeting ability (VEGFR-2 and NRP-1) and BBB penetration enhance gene delivery efficiency

• Nanoparticle Functionalization:

  • TAT-AT7 can be conjugated to nanoparticles carrying chemotherapeutic agents

  • This approach combines anti-angiogenic effects with direct cytotoxicity to glioma cells

• Multimodal Therapeutic Approaches:

  • Design of combination therapies where TAT-AT7 simultaneously inhibits angiogenesis and delivers other therapeutic payloads

  • Potential for synergistic effects through different mechanisms of action

• Imaging Agent Delivery:

  • TAT-AT7 can be coupled with imaging agents for theranostic applications

  • The preferential accumulation in glioma vasculature provides targeted imaging capabilities

For optimal delivery applications, researchers should consider:

• Conjugation chemistry that preserves both TAT-AT7's targeting ability and the therapeutic activity of the payload

• Optimal ratio of TAT-AT7 to payload for maximum efficacy

• Release kinetics in the target tissue for sustained therapeutic effect

What are the key considerations for translating TAT-AT7 research from preclinical models to potential clinical applications?

Translating TAT-AT7 research toward clinical applications requires addressing several critical considerations:

• Pharmacokinetic/Pharmacodynamic Optimization:

  • Determination of optimal dosing regimens

  • Assessment of circulation half-life and tissue distribution

  • Evaluation of clearance mechanisms and metabolism

• Safety Assessment:

  • Comprehensive toxicology studies in multiple species

  • Evaluation of potential off-target effects on normal vasculature

  • Assessment of immunogenicity and potential for antibody development

• Formulation Development:

  • Optimization of stability in various storage conditions

  • Development of appropriate delivery formulations

  • Scale-up considerations for GMP manufacturing

• Combination Strategy Development:

  • Identification of synergistic combinations with standard-of-care treatments

  • Determination of optimal sequencing of TAT-AT7 with other therapies

  • Evaluation of potential antagonistic interactions

• Patient Selection Biomarkers:

  • Assessment of VEGFR-2 and NRP-1 expression as potential predictive biomarkers

  • Identification of glioma subtypes most likely to respond

  • Development of companion diagnostics for therapeutic monitoring

How can researchers distinguish between direct anti-angiogenic effects and indirect tumor inhibition when evaluating TAT-AT7?

Distinguishing between direct anti-angiogenic effects and indirect tumor inhibition requires a methodical experimental approach:

• Sequential Time-Point Analysis:

  • Evaluate vascular changes (CD31 staining, vessel density) at early time points (24-48 hours)

  • Assess tumor cell proliferation (Ki-67) and apoptosis (TUNEL) at both early and later time points

  • Determine the temporal sequence of effects (vascular changes typically precede tumor response)

• Cell-Specific Effects Analysis:

  • Perform parallel in vitro experiments on endothelial cells and glioma cells

  • Compare dose-response relationships for both cell types

  • Evaluate receptor expression profiles (VEGFR-2, NRP-1) on both cell populations

• Conditioned Media Experiments:

  • Collect media from TAT-AT7-treated endothelial cells

  • Apply this conditioned media to glioma cells

  • Assess whether endothelial-derived factors mediate tumor effects

• Molecular Pathway Analysis:

  • Evaluate VEGFR-2 downstream signaling in both endothelial and tumor cells

  • Identify cell-type-specific signaling events

  • Use pathway inhibitors to determine causality in observed effects

• In Vivo Mechanistic Studies:

  • Use vascular-specific and tumor-specific genetic markers

  • Perform laser capture microdissection to separate vessel and tumor compartments

  • Analyze compartment-specific molecular changes after TAT-AT7 treatment

This methodological framework enables researchers to delineate the primary mechanisms and sequence of events in TAT-AT7's anti-glioma effects.

What are common pitfalls in TAT-AT7 experimental design and how can they be addressed?

Researchers working with TAT-AT7 should be aware of these common experimental pitfalls and their solutions:

Addressing these pitfalls will improve experimental reproducibility and enhance the translational value of TAT-AT7 research findings .

How should researchers interpret conflicting data on TAT-AT7 efficacy across different experimental models?

When faced with conflicting data on TAT-AT7 efficacy across different experimental models, researchers should employ a systematic interpretation approach:

• Model-Specific Factor Analysis:

  • Evaluate differences in receptor expression levels between models

  • Consider variations in vascular density and BBB integrity

  • Assess tumor heterogeneity and microenvironmental factors

• Methodological Variable Assessment:

  • Compare experimental protocols (timing, dosing, administration route)

  • Evaluate differences in endpoint measurements

  • Consider variations in analysis methods and quantification techniques

• Biological Context Integration:

  • Determine whether conflicts occur in specific biological contexts

  • Identify conditions where TAT-AT7 consistently shows efficacy

  • Define limitations where efficacy is compromised

• Statistical Rigour Evaluation:

  • Assess statistical power in conflicting studies

  • Consider effect sizes rather than just p-values

  • Evaluate reproducibility across independent experiments

• Mechanistic Resolution Approach:

  • Design experiments specifically to address the mechanism behind conflicts

  • Test hypotheses about model-specific factors that might explain differences

  • Use genetic or pharmacological manipulations to equalize key variables

This systematic approach can transform seemingly conflicting data into valuable insights about the contextual dependencies of TAT-AT7 efficacy.

What emerging technologies could enhance TAT-AT7 research and development?

Several emerging technologies have the potential to significantly advance TAT-AT7 research and development:

• Advanced Imaging Technologies:

  • Intravital microscopy for real-time visualization of TAT-AT7 distribution and effects

  • Super-resolution microscopy for detailed receptor interaction studies

  • PET tracers for non-invasive monitoring of TAT-AT7 biodistribution

• Organoid and 3D Culture Systems:

  • Patient-derived glioma organoids for personalized efficacy testing

  • BBB-on-a-chip models for improved penetration studies

  • Vascular organoids for anti-angiogenic mechanism studies

• CRISPR/Cas9 Applications:

  • Generation of receptor knockout models to validate specificity

  • Creation of reporter cell lines for real-time monitoring of pathway activation

  • In vivo genetic modifications to test TAT-AT7 in specific contexts

• AI-Driven Structure Optimization:

  • Computational modeling of TAT-AT7 interactions with VEGFR-2 and NRP-1

  • Machine learning approaches to predict optimal sequence modifications

  • In silico screening of variant peptides with enhanced properties

• Single-Cell Analysis Technologies:

  • Single-cell RNA-seq to identify cell-specific responses to TAT-AT7

  • Spatial transcriptomics to map effects within the tumor microenvironment

  • Mass cytometry for comprehensive protein-level response analysis

What key questions remain unanswered in TAT-AT7 research?

Despite significant progress in understanding TAT-AT7, several crucial questions remain unanswered:

• Receptor Binding Dynamics:

  • What is the precise molecular binding interface between TAT-AT7 and its receptors?

  • Are there conformational changes induced in VEGFR-2 or NRP-1 upon TAT-AT7 binding?

  • How does TAT-AT7 compete with different VEGF isoforms beyond VEGF-A165?

• Resistance Mechanisms:

  • Can tumor vasculature develop resistance to TAT-AT7 through receptor downregulation?

  • Are there compensatory angiogenic pathways activated following TAT-AT7 treatment?

  • How does the tumor microenvironment adapt to chronic TAT-AT7 exposure?

• Combination Therapy Optimization:

  • What is the optimal sequencing of TAT-AT7 with conventional therapies?

  • Which molecular targeted therapies would synergize most effectively with TAT-AT7?

  • How does TAT-AT7 affect the tumor immune microenvironment and potential immunotherapy combinations?

• Long-term Efficacy and Safety:

  • What are the effects of prolonged TAT-AT7 treatment on normal vasculature?

  • Is there potential for acquired immunogenicity with repeated administration?

  • How does TAT-AT7 affect wound healing and other physiological angiogenic processes?

• Predictive Biomarkers:

  • Which biomarkers can predict response to TAT-AT7 therapy?

  • Are there genetic signatures that indicate susceptibility or resistance?

  • Can liquid biopsy approaches monitor treatment response?

Addressing these questions will be essential for advancing TAT-AT7 toward clinical applications and optimizing its use in glioma treatment.